Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison

BACKGROUND: Recent meta-analyses have found a survival advantage with gemcitabine based combinations over single agent gemcitabine in patients with advanced pancreatic cancer. There is paucity of evidence in the form of direct head-to-head randomised controlled trials to determine which combinations...

Descripción completa

Detalles Bibliográficos
Autores principales: Sultana, Asma, Ghaneh, Paula, Cunningham, David, Starling, Naureen, Neoptolemos, John P, Smith, Catrin Tudur
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2474853/
https://www.ncbi.nlm.nih.gov/pubmed/18611273
http://dx.doi.org/10.1186/1471-2407-8-192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2474853/
https://www.ncbi.nlm.nih.gov/pubmed/18611273
http://dx.doi.org/10.1186/1471-2407-8-192

Ejemplares similares